1. Home
  2. PROV vs LUNG Comparison

PROV vs LUNG Comparison

Compare PROV & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

N/A

Current Price

$15.82

Market Cap

103.0M

Sector

Finance

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.78

Market Cap

82.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROV
LUNG
Founded
1956
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.0M
82.5M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
PROV
LUNG
Price
$15.82
$1.78
Analyst Decision
Hold
Buy
Analyst Count
2
7
Target Price
$16.25
$6.81
AVG Volume (30 Days)
7.2K
479.5K
Earning Date
01-27-2026
02-18-2026
Dividend Yield
3.50%
N/A
EPS Growth
N/A
N/A
EPS
0.90
N/A
Revenue
$39,823,000.00
$91,664,000.00
Revenue This Year
$4.14
$9.21
Revenue Next Year
$3.70
$5.03
P/E Ratio
$17.82
N/A
Revenue Growth
0.07
15.59
52 Week Low
$12.98
$1.31
52 Week High
$16.36
$9.37

Technical Indicators

Market Signals
Indicator
PROV
LUNG
Relative Strength Index (RSI) 54.16 35.31
Support Level $15.55 $1.92
Resistance Level $16.31 $2.03
Average True Range (ATR) 0.28 0.13
MACD -0.03 -0.07
Stochastic Oscillator 63.29 0.97

Price Performance

Historical Comparison
PROV
LUNG

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: